• Phone
  • Contact us
  • Locations
  • Search
  • Menu

share

  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Email this article
View or print a PDF of this page
.

 "...the product itself is just one component of a more holistic offering. This provider could well be a pharmaceutical company, whether alone or in partnership." 

GEORGE MACGINNIS, HEALTHCARE CONSULTING, PA CONSULTING GROUP

Adherence and the empowered patient

Peter Mansell
Eyeforpharma.com
29 June 2010

PA experts George MacGinnis and Bob Damms have given their views to eyeforpharma on how patient access to new technologies and new data could impact everything from compliance to cost-benefit analyses.

George comments that as the industry grapples with a complex 'service transition,' one that locates the product itself as just one component of a more holistic healthcare offering, this provider could well be a pharmaceutical company, whether alone or in partnership.

Bob Damms sees all this as part of a broader definition of personalised medicine that goes beyond technical advances in patient stratification to address issues of patient responsibility, public health, and lifestyle choices. At the same time, he adds, realising those concepts will require societal changes, including, in some cases, different systems of health coverage.

Where healthcare is free at the point of use, people tend to take it for granted and health is not valued in the same way as, say, looking good, Bob explains.

You can read the article in full here


To visit PA's healthcare pages, click here

NEWS UPDATES

Sign-up to receive company updates and press releases by email or newsfeed:

SIGN-UP

 

   
Corporate headquarters
123 Buckingham Palace Road
London SW1W 9SR London SW1W 9SR
United Kingdom
Tel: +44 20 7333 5865 Tel: +44 20 7333 5865
contact us now

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.

×